We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Assays Using ddPCR Quantify DNA Fragments

By LabMedica International staff writers
Posted on 14 May 2018
Print article
Image: The C1000 Touch thermal cycler (Photo courtesy of Bio-Rad).
Image: The C1000 Touch thermal cycler (Photo courtesy of Bio-Rad).
Optimized droplet digital polymerase chain reaction (ddPCR) assays have been developed that quantify short and long DNA fragments. These assays have been used to analyze plasma cell-free (cfDNA) fragment size distribution in human blood.

Circulating cell-free genome in human body fluids is being utilized as a source of genetic material for noninvasive screening, diagnostic and prognostic tests in clinical practice. Plasma cfDNA fragment size distribution provides important information required for diagnostic assay development.

Doctors at the University of Nebraska Medical Center (Omaha, NE, USA) and their colleagues collected blood samples from certified healthy donors and first trimester pregnant donors. Plasma was separated immediately after blood draw by two centrifugation steps. Exosomes were isolated from cell-free plasma using Invitrogen Total Exosome isolation from plasma kit.

Plasma and plasma exosome DNA was extracted using QIAamp Circulating Nucleic Acid Kit. Bio-Rad Automated Droplet Generator was used to generate droplets and thermal cycling was done using Bio-Rad C1000 Touch Thermal cycler. DNA extracted from blood plasma was analyzed using Agilent Bioanalyzer 2100 instrument and Agilent DNA High Sensitivity Kit.

The team developed and optimized four different EvaGreen chemistry based ddPCR assays to amplify four different amplicons with different sizes from human β-actin gene in order to accurately quantify cfDNA with different sizes in human blood plasma. They used concentrated human blood plasma cfDNA as genetic material for the development of these assays. These assays amplify 76, 135, 490 and 905 bp amplicons from human β-actin gene.

The study showed that cfDNA in human blood plasma has two localizations. Blood plasma exosomes are one such localization harboring cfDNA of mostly small fragments. About 72% of cfDNA localized in exosomes are small DNA fragments, less than 490 bp. Blood plasma apoptotic bodies and nucleuses are the other localizations where cfDNA is present. DNA concentration in plasma pellet was seven-fold higher than plasma cfDNA.

The authors concluded that non-pregnant plasma cell-free and exosome DNA share a unique fragment distribution pattern, which is different from pregnant donor plasma and exosome DNA fragment distribution indicating the effect of physiological status on cfDNA fragment size distribution. Fragment distribution pattern for plasma pellet that includes apoptotic bodies and nuclear DNA was greatly different from plasma cell-free and exosome DNA. The study was published online on April 12, 2018, in the journal Clinica Chimica Acta.

Related Links:
University of Nebraska Medical Center

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.